logo-loader
viewKromek Group PLC

Kromek CZT detectors to be used in medical imaging during cancer surgery

The detection specialist is working with medical imaging firm Adaptix and the University of Manchester to develop a pathology cabinet that will provide 3D images offering accurate differentiation between cancerous and healthy tissue

Kromek Group PLC - Kromek CZT detectors to be used in medical imaging during cancer surgery

Kromek Group PLC (LON:KMK) said it has started development of a new system to improve pathological medical imaging techniques used during cancer surgery to distinguish between healthy and non-healthy tissue.

The detection technology specialist said the three-year project, which has received a grant from Innovate UK and is being conducted in partnership with medical imaging firm Adaptix and the University of Manchester, is aiming to develop a prototype of a new type of pathology cabinet, based on Kromek's CZT detectors and Adaptix's Flat Panel X-Ray Source technology.

WATCH: Kromek Group says 2019-20 was 'operationally a very strong, successful year'

The prototype will produce high-resolution 3D images that provide more accurate differentiation of the boundaries between cancerous and healthy tissue, enabling surgeons to remove the minimum amount of healthy tissue when extracting cancer tumours and reduce the risk of more than one operation being needed and of cancer spreading from diseased tissue left after the initial surgery.

It is not the first instance of Kromek’s CZT being used in medical devices, with the technology currently used for early detection of diseases such as breast cancer, cardiac conditions and osteoporosis.

"This is an exciting project for Kromek as it takes our CZT-based detectors into a new application area. Our technology is already being used by leading OEMs to enable the early diagnosis of cancer. With this system, we will contribute to improving the outcome of surgeries through greater image quality”, Kromek chief executive Arnab Basu said in a statement.

“It will reduce the risk of diseased tissue remaining and further surgeries being required while minimising the removal of healthy tissue, which will be of great benefit to both healthcare providers and patients. We look forward to working alongside our partners, Adaptix and the University of Manchester, to complete the development of this new system and take it to the next stage", he added.

Shares in Kromek rose 4.1% to 13.7p in early trading on Wednesday.

Quick facts: Kromek Group PLC

Price: 13 GBX

AIM:KMK
Market: AIM
Market Cap: £44.8 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kromek Group PLC named herein, including the promotion by the Company of Kromek Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Kromek Group says 2019-20 was 'operationally a very strong, successful year'

Kromek Group PLC's (LON:KMK) Arnab Basu talks to Proactive London after reporting their final results for the year ending on 30 April 2020. Basu explains that revenue has was £13.1m compared with £14.5m the previous year. He says despite the challenges of Covid-19, 2019-2020 was...

2 weeks, 5 days ago

2 min read